Open Access

Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer

Corrigendum in: /10.3892/ol.2021.12772

  • Authors:
    • Norihiko Suzuki
    • Fumio Nakagawa
    • Teiji Takechi
  • View Affiliations

  • Published online on: May 26, 2017     https://doi.org/10.3892/ol.2017.6258
  • Pages: 639-646
  • Copyright: © Suzuki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A number of patients exhibit peritoneal dissemination of gastric or colorectal cancer, which is a predominant cause of cancer‑associated mortality. Currently, there is no markedly effective treatment available. The present study was designed to determine the efficacy of trifluridine/tipiracil (TFTD), formerly known as TAS‑102, which is used for the treatment of patients with unresectable advanced or recurrent colorectal cancer refractory to standard therapies. Four colorectal cancer cell lines and one gastric cancer cell line were intraperitoneally inoculated into nude mice, as models of peritoneal dissemination. TFTD (200 mg/kg/day) was orally administered for 5 consecutive days followed by 2 drug‑free days for 6 weeks. The increase in the lifespan (ILS) of the TFTD‑treated mice compared with that of the drug‑free control mice was 66.7, 43.3, 106.3, 98.3 and 133.3% for DLD‑1, DLD‑1/5‑fluorouracil [5‑fluorouracil (5FU)‑resistant subline of DLD‑1], HT‑29 and HCT116 colorectal cancer cell lines, and MKN45 gastric cancer cell line, respectively. This ILS was similar to that of the irinotecan‑treated mice (ILS, 70‑84%), but was significantly (P<0.05) increased compared with that of the 5FU‑, tegafur, gimeracil and potassium oxonate‑ and cisplatin‑treated mice (ILS, 1‑53%, 0.8‑60% and 85%, respectively). No significant increase in body weight loss was observed during the dosing periods with any of the drugs used. The increase in CEA levels with progressive peritoneal dissemination was inhibited by TFTD treatment. TFTD also exhibited marked anticancer effects against Kirsten rat sarcoma viral oncogene homolog‑mutated tumors and 5FU‑resistant tumors. The results of the present study indicate that TFTD may be a potential drug against peritoneal dissemination of colorectal and/or gastric cancer in humans and may be utilized for chemo‑naïve tumors and recurrent tumors following 5FU treatment.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 14 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Suzuki N, Nakagawa F and Takechi T: Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer Corrigendum in /10.3892/ol.2021.12772. Oncol Lett 14: 639-646, 2017
APA
Suzuki, N., Nakagawa, F., & Takechi, T. (2017). Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer Corrigendum in /10.3892/ol.2021.12772. Oncology Letters, 14, 639-646. https://doi.org/10.3892/ol.2017.6258
MLA
Suzuki, N., Nakagawa, F., Takechi, T."Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer Corrigendum in /10.3892/ol.2021.12772". Oncology Letters 14.1 (2017): 639-646.
Chicago
Suzuki, N., Nakagawa, F., Takechi, T."Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer Corrigendum in /10.3892/ol.2021.12772". Oncology Letters 14, no. 1 (2017): 639-646. https://doi.org/10.3892/ol.2017.6258